Marker Therapeutics (MRKR) Liabilities and Shareholders Equity (2010 - 2026)

Marker Therapeutics (MRKR) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $17.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 2.59% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $73.0 million (up 18.52% YoY), while the FY2025 annual figure was $19.1 million, down 13.4% from the prior year.
• Liabilities and Shareholders Equity fell to $17.4 million in Q1 2026 per MRKR's latest filing, from $19.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $55.0 million in Q1 2022 and bottomed at $10.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $24.6 million across 5 years, with a median of $19.5 million in 2023.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 58.04% — and 2025, when it soared 99.21%.
• Marker Therapeutics' Liabilities and Shareholders Equity stood at $34.4 million in 2022, then sank by 50.24% to $17.1 million in 2023, then increased by 28.58% to $22.0 million in 2024, then declined by 13.4% to $19.1 million in 2025, then decreased by 8.58% to $17.4 million in 2026.
• Business Quant data shows MRKR's Liabilities and Shareholders Equity at $17.4 million in Q1 2026, $19.1 million in Q4 2025, and $21.7 million in Q3 2025.